Display options
Cite
Kingma SD, Wagemans T, IJlst L, et al. Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse Model. JIMD Rep. 2015;23:77-83doi: 10.1007/8904_2015_432.
Kingma, S. D., Wagemans, T., IJlst, L., Seppen, J., Gijbels, M. J., Wijburg, F. A., & van Vlies, N. (2015). Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse Model. JIMD reports, 2377-83. https://doi.org/10.1007/8904_2015_432
Kingma, Sandra D K, et al. "Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse Model." JIMD reports vol. 23 (2015): 77-83. doi: https://doi.org/10.1007/8904_2015_432
Kingma SD, Wagemans T, IJlst L, Seppen J, Gijbels MJ, Wijburg FA, van Vlies N. Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse Model. JIMD Rep. 2015;23:77-83. doi: 10.1007/8904_2015_432. Epub 2015 Apr 09. PMID: 25854773; PMCID: PMC4484902.
Copy Download .nbib Format: NLM
Share it on

JIMD Rep. 2015;23:77-83. doi: 10.1007/8904_2015_432. Epub 2015 Apr 09.

Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse Model.

JIMD reports

Sandra D K Kingma, Tom Wagemans, Lodewijk IJlst, Jurgen Seppen, Marion J J Gijbels, Frits A Wijburg, Naomi van Vlies

Affiliations

  1. Department of Pediatrics and Amsterdam Lysosome Centre "Sphinx", Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

PMID: 25854773 PMCID: PMC4484902 DOI: 10.1007/8904_2015_432

Abstract

Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder characterized by diminished degradation of the glycosaminoglycans heparan sulfate (HS) and dermatan sulfate (DS). Patients present with a variety of symptoms, including severe skeletal disease. Current therapeutic strategies have only limited effects on bone disease. The isoflavone genistein has been studied as a potential therapy for the mucopolysaccharidoses because of its putative ability to inhibit GAG synthesis and subsequent accumulation. Cell, animal, and clinical studies, however, showed variable outcomes. To determine the effects of genistein on MPS I-related bone disease, wild-type (WT) and MPS I mice were fed a genistein-supplemented diet (corresponding to a dose of approximately 160 mg/kg/day) for 8 weeks. HS and DS levels in bone and plasma remained unchanged after genistein supplementation, while liver HS levels were decreased in genistein-fed MPS I mice as compared to untreated MPS I mice. Unexpectedly, genistein-fed mice exhibited significantly decreased body length and femur length. In addition, 60% of genistein-fed MPS I mice developed a scrotal hernia and/or scrotal hydrocele, manifestations, which were absent in WT or untreated MPS I mice. In contrast to studies in MPS III mice, our study in MPS I mice demonstraes no beneficial but even potential adverse effects of genistein supplementation. Our results urge for a cautious approach on the use of genistein, at least in patients with MPS I.

References

  1. J Inherit Metab Dis. 2014 Jul;37(4):587-98 - PubMed
  2. PLoS One. 2010 Dec 01;5(12):e14192 - PubMed
  3. J Inherit Metab Dis. 2013 Mar;36(2):247-55 - PubMed
  4. Mol Genet Metab. 2009 Nov;98(3):235-42 - PubMed
  5. J Biol Chem. 1987 Apr 25;262(12):5592-5 - PubMed
  6. Mol Genet Metab. 2013 Aug;109(4):382-5 - PubMed
  7. Mol Genet Metab. 2013 May;109(1):33-40 - PubMed
  8. Phytochemistry. 2002 Jun;60(3):205-11 - PubMed
  9. Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v26-33 - PubMed
  10. Cancer Res. 2001 Sep 15;61(18):6777-82 - PubMed
  11. J Pediatr Orthop. 2004 Jan-Feb;24(1):97-101 - PubMed
  12. Toxicol Appl Pharmacol. 2000 Apr 15;164(2):206-15 - PubMed
  13. J Nutr. 1997 May;127(5 Suppl):838S-841S - PubMed
  14. Bone Marrow Transplant. 2002 Aug;30(4):215-22 - PubMed
  15. Toxicol Appl Pharmacol. 2012 Nov 1;264(3):335-42 - PubMed
  16. Am J Med Genet A. 2011 Sep;155A(9):2257-62 - PubMed
  17. Mol Genet Metab. 2007 Feb;90(2):171-80 - PubMed
  18. J Biol Chem. 2014 Jun 13;289(24):17054-69 - PubMed
  19. Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v4-12 - PubMed
  20. Hum Mol Genet. 1997 Apr;6(4):503-11 - PubMed
  21. J Nutr. 2000 Jul;130(7):1665-9 - PubMed
  22. Br J Pharmacol. 2010 Mar;159(5):1082-91 - PubMed
  23. Ann Rheum Dis. 2009 Nov;68(11):1659-65 - PubMed
  24. J Pediatr. 2009 Jun;154(6):859-64.e3 - PubMed
  25. Am J Pathol. 2000 Mar;156(3):925-38 - PubMed
  26. J Inherit Metab Dis. 2014 Sep;37(5):813-21 - PubMed
  27. Genes Brain Behav. 2011 Aug;10(6):673-82 - PubMed
  28. J Biomed Sci. 2009 Mar 02;16:26 - PubMed
  29. J Chromatogr A. 2005 May 6;1073(1-2):317-22 - PubMed
  30. Clin Neuropathol. 1983;2(3):122-7 - PubMed
  31. Endocrinology. 2003 Aug;144(8):3315-20 - PubMed
  32. Biomed Res Int. 2014;2014:619617 - PubMed

Publication Types